Real life experience of mycophenolate mofetil monotherapy in liver transplant patients

International audienceBACKGROUND: Mycophenolate mofetil (MMF) monotherapy following liver transplantation (LT) remains controversial due to a risk of acute rejection. The aim of this study was to report the largest multicenter experience of the use a MMF monotherapy guided by therapeutic drug monitoring using pharmacoslope modeling and Bayesian estimations of the MPA inter-dose AUC (BEMPAMETHODS: MMF daily doses were adjusted to reach the BEMPARESULTS: From 2000-2014, in 2 transplantation centers, 94 liver transplant recipients received MMF monotherapy 6.5±4 years after LT. The mean BEMPACONCLUSIONS: MMF monotherapy regimen appears usually safe and beneficial, with low risk of acute rejection and eGFR improvement. Therapeutic drug monitoring strategy seemed useful by identifying 14% of patients with low MMF exposure

Sofosbuvir plus velpatasvir plus voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, AUSTRIA, APR 10-14, 2019International audienc

Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, NOV 09-13, 2018International audienc

Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, NOV 09-13, 2018International audienc

Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, NOV 09-13, 2018International audienc

Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, NOV 09-13, 2018International audienc

No evidence of hepatitis B virus reactivation among liver transplant recipients treated with interferon- free regimens for hepatitis C virus recurrence (ANRS CO23 CUPILT Cohort)

International audienc